← Leaderboards
Zheng David Qian
Oregon Health & Science University
$4,913,102
Attributed
$4,913,102
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $768.8K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,913,102 · 4
By mechanism
R01$4,913,102 · 4
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Nathalie Pamir$4,494,706
- Chad Cameron Hagen$927,474
- Tamara Hayes$429,862
- Jon D Raybuck$52,190
- Paul Kievit$12,790,994
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroIn VivoXenograft ProcedureGrowthMediatingCancer PatientMalignant NeoplasmsHypoxia Inducible Factor 1Animal ModelProteinsClinical TrialsMetabolismMetabolicMolecularImmunohistochemistryOncogenicTumorBiologicalGlutaminePathway InteractionsResistanceMolecular TargetProtein DegradationOverexpression
Grant awards (16)
Developing therapies to improve enzalutamide in CRPC$416,508
R01 · FY2025 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$123,201
R01 · FY2025 · CA · contact PI
Developing therapies to improve enzalutamide in CRPC$395,685
R01 · FY2024 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$334,662
R01 · FY2024 · CA · contact PI
Developing therapies to improve enzalutamide in CRPC$416,508
R01 · FY2023 · CA · contact PI
Adaptive resistance to AR inhibitors in hypoxia by GPT1$352,275
R01 · FY2023 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,232
R01 · FY2020 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$341,648
R01 · FY2019 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,269
R01 · FY2018 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,147
R01 · FY2017 · CA · contact PI
Adaptive resistance to HIF1a inhibition in hypoxia$352,242
R01 · FY2016 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$220,610
R01 · FY2014 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$213,786
R01 · FY2013 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$227,432
R01 · FY2012 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$227,432
R01 · FY2011 · CA · contact PI
HIF1a N-terminus hyperacetylation and anticancer mechanism of hydroxamic-HDACi$234,465
R01 · FY2010 · CA · contact PI